Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…

A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…

A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…

Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…

On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways from ASH’s official reports.